Author Archives: Guest Blogger

Breaking Point? The Cost of Oncology Care in the U.S.

The US healthcare system is expected to spend more than $150 billion treating cancer by 2020. In this PharmExec article, Daniele Severi Bruni, Jacob J. Schutz, and Anthony Hewitt of Icon plc ask if we have we have hit a breaking point in the escalating cost of oncology care. Click here for the article.
Posted in healthcare | Tagged | Leave a comment

Is There Potential for Growth in Brazil’s Phytotherapic Drug Market?

It is well known that Brazil has an immense biodiversity and that the Amazon is the largest tropical rainforest in the world. Traditional Brazilian medicines include African elements, rooted on indigenous groups. Few pharmaceutical companies, however, know at what level phytotherapic drugs are commercialized in the country, how much regulation is imposed for herbal medicines, […]
Posted in Emerging Markets, Global, Guest Blog | Tagged , , , , | Leave a comment

EMA Responds Robustly to Conflict-of-Interest Claims

By Philip Ward, Applied Clinical Trials. The European Medicines Agency (EMA) has insisted that the concerns raised about its scientific advice given to pharmaceutical companies stem from a flawed understanding of the activities of the agency and its partners in this area.
Posted in Europe, Global, Guest Blog, Regulatory | Tagged , , , , , | Leave a comment

The Medical Technology Disconnect

By Doug Mowen. The medical technology industry has a legacy of creating life-enhancing, life-extending products while rewarding its investors in the process. In fact, this connection between innovation and profitability has been a fundamental driver in the C-suites and boardrooms of many medical device, diagnostics and equipment companies. But change is underway. Dominating external forces […]
Posted in Technology | Tagged , | Leave a comment

CMOs Take a Hit as Payers Refuse to Cover New Drugs

By Jim Miller. The value of the customer relationship to a CMO is a function of two variables: unit volume and price per unit. Both variables are contentious issues: bio/pharmaceutical companies are putting enormous pressure on their CMOs for lower prices, while their inability to deliver forecasted volumes often means lost revenues for CMOs as […]
Posted in Europe, Global, Guest Blog, pricing | Tagged , , , | Leave a comment
  • Categories

  • Meta